Table 6.
Baseline characteristics and follow-up information of infection and infective death group and noninfection group of corticosteroid users
| Baseline characteristic | Infection and infective death (n = 18, 4.9%) |
Noninfection (n = 351, 95.1%) |
P value |
|---|---|---|---|
| Male (n [%])/female (n) | 8 (44.4)/10 | 158 (45.0)/193 | 0.962 |
| Age (yr) | 38 ± 15 | 34 ± 13 | 0.145 |
| Initial dosage of corticosteroid (mg/d) | 46 ± 11 | 48 ± 7 | 0.557 |
| Corticosteroid pulse | 1 (5.6) | 47 (13.4) | 0.545 |
| Reuse of corticosteroid | 3 (16.7) | 41 (11.7) | 0.461 |
| Corticosteroid plus immunosuppressant | 14 (77.8) | 205 (58.4) | 0.103 |
| Cyclophosphamide | 11 (61.1) | 159 (45.3) | |
| Tacrolimus | 3 (16.7) | 11 (3.1) | |
| Leflunomide | 0 (0) | 24 (6.8) | |
| Mycophenolate mofetil | 4 (22.2) | 16 (4.6) | |
| Cyclosporine A | 2 (11.1) | 29 (8.3) | |
| Systolic BP (mm Hg) | 133 ± 18 | 124 ± 16 | 0.021 |
| Diastolic BP (mm Hg) | 84 ± 9 | 80 ± 12 | 0.124 |
| Mean arterial pressure (mm Hg) | 100 ± 11 | 95 ± 12 | 0.045 |
| Serum creatinine (mmol/l) | 130 (100–192) | 104 (79–143) | 0.030 |
| Proteinuria (g/24 h) | 4.7 (2.2–6.8) | 3.0 (1.7–5.2) | 0.120 |
| eGFR (ml/min per 1.73 m2) | 54 ± 27 | 74 ± 33 | 0.010 |
| Uric acid (μmol/l) | 409 ± 111 | 386 ± 101 | 0.343 |
| Hemoglobin (g/l) | 130 ± 22 | 133 ± 20 | 0.549 |
| Albumin (g/l) | 33 ± 7 | 34 ± 8 | 0.576 |
| Triglyceride (mmol/l) | 2.0 ± 0.7 | 2.2 ± 1.6 | 0.510 |
| Total cholesterol (mmol/l) | 6.0 ± 2.8 | 5.9 ± 2.1 | 0.927 |
| Follow-up (mo) | 28 (8–63) | 49 (25–84) | 0.019 |
| ESRD | 8 (44.4) | 47 (13.4) | 0.001 |
| CKD stage | |||
| 1 | 2 (1.7) | 114 (98.3) | 0.021 |
| 2 | 5 (4.6) | 103 (95.4) | |
| 3 | 8 (6.9) | 108 (93.1) | |
| 4/5 | 3 (10.3) | 26 (89.7) |
Unless otherwise indicated values are n (%), means ± SDs, or median (25th–75th centiles). Bold values are statistically significant.
BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; SAEs, severe adverse effects.